Published in Surg Today on January 26, 2012
Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients. Exp Hematol Oncol (2017) 0.75
Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74
Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med (1990) 3.88
Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant (2004) 3.25
Reticulum cell sarcoma after renal homotransplantation and azathioprine and prednisone therapy. Br Med J (1968) 2.52
How I treat EBV lymphoproliferation. Blood (2009) 2.18
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood (2005) 1.99
Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation (2003) 1.88
Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation (1999) 1.70
Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation (2005) 1.62
18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica (2006) 1.61
Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant (1992) 1.54
Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation (2001) 1.53
Use of EBV PCR for the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patients. Am J Transplant (2002) 1.49
Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol (1998) 1.49
Post-transplant lymphoproliferative disorder after adult-to-adult living donor liver transplant: case series and review of literature. Leuk Lymphoma (2010) 1.41
Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis (1995) 1.39
Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer (2005) 1.29
Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant (2005) 1.26
Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol (1995) 1.19
Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases? Transplantation (2005) 1.17
Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg (2002) 1.16
Posttransplant primary CNS lymphoma. Neuro Oncol (2000) 1.16
Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome. Transplantation (2002) 1.15
Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation. Transpl Int (2007) 1.14
Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant (2005) 1.13
Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol (2005) 1.11
Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology (1998) 1.09
EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. Am J Transplant (2008) 1.08
Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation (1998) 1.05
A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. Transplantation (1998) 1.02
Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab. Transplantation (2007) 0.98
Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients. Transplantation (2003) 0.95
Early onset post-transplant lymphoproliferative disease is associated with allograft localization. Clin Transplant (2005) 0.94
Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol (2005) 0.92
Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. Transplantation (2003) 0.91
FDG PET imaging in the evaluation of post-transplant lymphoproliferative disorder following renal transplantation. Nucl Med Commun (2005) 0.87
Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. Clin Transplant (2006) 0.86
Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients. Transplantation (2007) 0.86
Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder. Clin Transplant (2003) 0.86
Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab. Transpl Int (2006) 0.85
Usefulness of quantitative real-time polymerase chain reaction in following up patients with Epstein-Barr virus infection after liver transplantation. Clin Transplant (2000) 0.85
Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients. Transplantation (2002) 0.85
Positron emission tomography with fluoro-2-deoxy-D-glucose (FDG-PET) in the staging of post transplant lymphoproliferative disorder in lung transplant recipients. J Thorac Imaging (2004) 0.84
Efficacy and safety of basiliximab with a tacrolimus-based regimen in liver transplant recipients. Transplantation (2004) 0.83
Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment. Haematologica (2002) 0.82
PTLD visualization by FDG-PET: improved detection of extranodal localizations. Am J Transplant (2006) 0.81
Clinical and pathological features of posttransplantation lymphoproliferative disorders presenting with skin involvement in 4 patients. Arch Dermatol (2004) 0.79
Indications and results of chemotherapy in children with posttransplant lymphoproliferative disease after liver transplantation. Transplantation (2000) 0.79
Who is at risk for post-transplant lymphoproliferative disorders (PTLD) after liver transplantation? J Hepatol (2005) 0.79
Primary extranodal non-Hodgkin's lymphoma of the common bile duct manifesting as obstructive jaundice: report of a case. Surg Today (2009) 0.78
Epstein-Barr virus infection after pediatric living-related liver transplantation--management and risk factors. Transplant Proc (2010) 0.77
Decreasing the Epstein-Barr virus load by adjusting the FK506 blood level. Transpl Int (2002) 0.77
Steroid-resistant late acute rejection after a living donor liver transplantation: case report and review of the literature. Tohoku J Exp Med (2007) 0.76
Cytomegalovirus infection and posttransplant lymphoproliferative disease in renal transplant recipients: results of the U.S. multicenter FK506 Kidney Transplant Study Group. Transplantation (1999) 0.75
Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature (2007) 7.07
Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity (2006) 4.75
Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. J Immunol (2004) 2.28
Carbon monoxide suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury. Nat Med (2003) 2.15
Operative morbidity of living liver donors in Japan. Lancet (2003) 2.13
Molecular explanation for the contradiction between systemic Th17 defect and localized bacterial infection in hyper-IgE syndrome. J Exp Med (2009) 2.08
A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J Hum Genet (2010) 1.97
Allelic and non-allelic heterogeneities in pyridoxine dependent seizures revealed by ALDH7A1 mutational analysis. Mol Genet Metab (2007) 1.75
Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hematol (2005) 1.65
The analysis of the functions of human B and T cells in humanized NOD/shi-scid/gammac(null) (NOG) mice (hu-HSC NOG mice). Int Immunol (2009) 1.59
Extracorporeal shock wave therapy improves the walking ability of patients with peripheral artery disease and intermittent claudication. Circ J (2012) 1.55
Somatotopic distribution of peri-rolandic spikes may predict prognosis in pediatric-onset epilepsy with sensorimotor seizures. Clin Neurophysiol (2010) 1.48
The model for end-stage liver disease score is useful for predicting economic outcomes in adult cases of living donor liver transplantation. J Gastroenterol (2006) 1.47
Patients with Epstein-Fechtner syndromes owing to MYH9 R702 mutations develop progressive proteinuric renal disease. Kidney Int (2010) 1.46
Living-related intestinal transplantation for a patient with hypoganglionosis. Pediatr Transplant (2006) 1.39
A newly developed small-caliber videoduodenoscope for endoscopic retrograde cholangiopancreatography in children. J Clin Gastroenterol (2003) 1.39
Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis (2003) 1.36
Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol (2009) 1.26
Clinical characteristics and management of congenital esophageal stenosis: a report on 14 cases. J Pediatr Surg (2003) 1.23
Intestinal obstruction caused by colonic metastasis from intrahepatic cholangiocarcinoma 6 years after removal of the primary tumor: report of a case. Surg Today (2012) 1.21
Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study. Endocr J (2005) 1.19
Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: overlapping clinical manifestations with Costello syndrome. Am J Med Genet A (2007) 1.18
Intraductal tubulopapillary neoplasms of the pancreas distinct from pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol (2009) 1.18
Validation of the multiple sensor mechanism of the Keap1-Nrf2 system. Free Radic Biol Med (2012) 1.18
Pathogenesis of hepatitis C virus infection in Tupaia belangeri. J Virol (2010) 1.17
Cadmium induces nuclear export of Bach1, a transcriptional repressor of heme oxygenase-1 gene. J Biol Chem (2003) 1.16
Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys (2009) 1.16
Two functional coding single nucleotide polymorphisms in STK15 (Aurora-A) coordinately increase esophageal cancer risk. Cancer Res (2005) 1.15
Inhibitor of apoptosis protein family as diagnostic markers and therapeutic targets of colorectal cancer. Surg Today (2011) 1.14
Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells. DNA Repair (Amst) (2004) 1.14
Diagnosis of autoimmune pancreatitis by EUS-FNA by using a 22-gauge needle based on the International Consensus Diagnostic Criteria. Gastrointest Endosc (2012) 1.13
Dissecting the instant blood-mediated inflammatory reaction in islet xenotransplantation. Xenotransplantation (2008) 1.12
Characterization of the epithelial cell adhesion molecule (EpCAM)+ cell population in hepatocellular carcinoma cell lines. Cancer Sci (2010) 1.10
Characterization of two cytoplasmic poly(A)-binding proteins, PABPC1 and PABPC2, in mouse spermatogenic cells. Biol Reprod (2008) 1.08
Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation. Hum Mutat (2010) 1.08
Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J Immunol (2008) 1.07
Defective IL-10 signaling in hyper-IgE syndrome results in impaired generation of tolerogenic dendritic cells and induced regulatory T cells. J Exp Med (2011) 1.06
Lentiviral vector-mediated gene transfer in T cells from Wiskott-Aldrich syndrome patients leads to functional correction. Mol Ther (2004) 1.06
Vasohibin prevents arterial neointimal formation through angiogenesis inhibition. Biochem Biophys Res Commun (2006) 1.05
Octa-arginine mediated delivery of wild-type Lnk protein inhibits TPO-induced M-MOK megakaryoblastic leukemic cell growth by promoting apoptosis. PLoS One (2011) 1.05
Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells. Cancer Sci (2009) 1.04
High incidence of reflux esophagitis observed by routine endoscopic examination after gastric pull-up esophagectomy. World J Surg (2003) 1.04
HNF1B alterations associated with congenital anomalies of the kidney and urinary tract. Pediatr Nephrol (2010) 1.03
Postoperative corticosteroid therapy for bile drainage in biliary atresia--a nationwide survey. J Pediatr Surg (2004) 1.02
Persistent expression of the full genome of hepatitis C virus in B cells induces spontaneous development of B-cell lymphomas in vivo. Blood (2010) 1.01
Ubiquitin C-terminal hydrolase L-1 is essential for the early apoptotic wave of germinal cells and for sperm quality control during spermatogenesis. Biol Reprod (2005) 1.01
Developmental regulation of ubiquitin C-terminal hydrolase isozyme expression during spermatogenesis in mice. Biol Reprod (2004) 1.01
All-trans retinoic acid induces in vitro angiogenesis via retinoic acid receptor: possible involvement of paracrine effects of endogenous vascular endothelial growth factor signaling. Endocrinology (2006) 1.01
Intraductal papillary mucininous neoplasm of the bile ducts: multimodality assessment with pathologic correlation. Abdom Imaging (2011) 1.01
A homozygous mutation of voltage-gated sodium channel β(I) gene SCN1B in a patient with Dravet syndrome. Epilepsia (2012) 1.01
Effects of age at Kasai portoenterostomy on the surgical outcome: a review of the literature. Surg Today (2014) 1.00
Somatic mutations in PIK3CA and activation of AKT in intraductal tubulopapillary neoplasms of the pancreas. Am J Surg Pathol (2011) 1.00
Genetic analysis of Shwachman-Diamond syndrome: phenotypic heterogeneity in patients carrying identical SBDS mutations. Tohoku J Exp Med (2005) 1.00
Solid pseudopapillary neoplasms of the pancreas: an 18-year experience at a single Japanese Institution. Surg Today (2012) 1.00
Attention-deficit and hyperactive neurobehavioural characteristics induced by perinatal hypothyroidism in rats. Behav Brain Res (2004) 0.99
Outcome in patients with Wiskott-Aldrich syndrome following stem cell transplantation: an analysis of 57 patients in Japan. Br J Haematol (2006) 0.99
Two closely related ubiquitin C-terminal hydrolase isozymes function as reciprocal modulators of germ cell apoptosis in cryptorchid testis. Am J Pathol (2004) 0.99
A case surviving for over a year of renal tubular dysgenesis with compound heterozygous angiotensinogen gene mutations. Am J Med Genet A (2006) 0.99
Phage phiC31 integrase-mediated genomic integration of the common cytokine receptor gamma chain in human T-cell lines. J Gene Med (2006) 0.98
High expression of ncRAN, a novel non-coding RNA mapped to chromosome 17q25.1, is associated with poor prognosis in neuroblastoma. Int J Oncol (2009) 0.97
Living-donor liver transplantation for homozygous familial hypercholesterolemia from a donor with heterozygous hypercholesterolemia. Transpl Int (2003) 0.97
Connective tissue growth factor is overexpressed in muscles of human muscular dystrophy. J Neurol Sci (2007) 0.97
Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol (2013) 0.97
Maternal feeding controls fetal biological clock. PLoS One (2008) 0.96
Self-enhancement of hepatitis C virus replication by promotion of specific sphingolipid biosynthesis. PLoS Pathog (2012) 0.96
Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor. Pancreas (2002) 0.96
Experimental study on tissue engineering of the small intestine by mesenchymal stem cell seeding. J Surg Res (2002) 0.95
Heterogeneous expression of DNA-dependent protein kinase in esophageal cancer and normal epithelium. Int J Mol Med (2006) 0.95
5-fu metabolism in cancer and orally-administrable 5-fu drugs. Cancers (Basel) (2010) 0.95
Cronkhite-Canada syndrome complicated with huge intramucosal gastric cancer. Gastric Cancer (2009) 0.95
Novel Artemis gene mutations of radiosensitive severe combined immunodeficiency in Japanese families. Hum Genet (2003) 0.95
Molecular analysis of a presymptomatic case of carnitine palmitoyl transferase I (CPT I) deficiency detected by tandem mass spectrometry newborn screening in Japan. Brain Dev (2009) 0.95
Treatment responses of childhood aplastic anaemia with chromosomal aberrations at diagnosis. Br J Haematol (2002) 0.95
A further case of renal tubular dysgenesis surviving the neonatal period. Eur J Pediatr (2008) 0.94
Tumor-associated tissue eosinophilia in human esophageal squamous cell carcinoma. Anticancer Res (2006) 0.94
Mutation and haplotype analyses of the MUT gene in Japanese patients with methylmalonic acidemia. J Hum Genet (2006) 0.94
Risks of donation and quality of donors' life after living donor liver transplantation. Transpl Int (2005) 0.93
Functional characterization of a new p53 mutant generated by homozygous deletion in a neuroblastoma cell line. Biochem Biophys Res Commun (2007) 0.93
Cholangiocarcinoma arising from preexisting biliary hamartoma of liver--report of a case. Hepatogastroenterology (2003) 0.93
Brain death in combination with warm ischemic stress during isolation procedures induces the expression of crucial inflammatory mediators in the isolated islets. Cell Transplant (2010) 0.92
Use of older controlled non-heart-beating donors for liver transplantation. Transplantation (2003) 0.92
Intraductal papillary mucinous neoplasm originating from a jejunal heterotopic pancreas: report of a case. Surg Today (2013) 0.92
The significance of preserving the energy status and microcirculation in liver grafts from non-heart-beating donor. Cell Transplant (2008) 0.92
Runt-related transcription factor 2 in human colon carcinoma: a potent prognostic factor associated with estrogen receptor. Int J Cancer (2012) 0.92
Impact of age at Kasai operation on short- and long-term outcomes of type III biliary atresia at a single institution. J Pediatr Surg (2010) 0.91
Effect of portocaval shunt on residual extreme small liver after extended hepatectomy in porcine. World J Surg (2006) 0.91